Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-142 in Idiopathic Pulmonary Fibrosis
2024-518013-25-00Phase 2Authorised
- Sponsor
- AbbVie Inc.
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 22
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing ABBV-142 with Placebo (2 arms). Primary endpoint: Absolute change from baseline in FVC (mL) at Week 24. Planned start Jul 2026; status: authorised.
02
Drugs
ABBV-142
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2024-518013-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518013-25-00.